SPRAVATO Billing Codes 2026: Drug, Observation, and Payer Workflow
A 2026 SPRAVATO and esketamine billing workflow for G2082, G2083, payer-specific alternatives, REMS, drug acquisition, observation, authorization, claims, and denials.
On this page: Direct answer
Direct answer
SPRAVATO billing codes 2026: what operators need to know
A 2026 SPRAVATO and esketamine billing workflow for G2082, G2083, payer-specific alternatives, REMS, drug acquisition, observation, authorization, claims, and denials. Confirm whether the payer expects a bundled encounter or separate drug and professional reporting. Do not infer current Medicare coverage from a code's existence or an old contractor article.
SPRAVATO billing is not one code lookup. A claim may need to represent the drug, supervised self-administration, required observation, the qualified setting, REMS status, payer coverage, authorization, acquisition pathway, dose, diagnosis, and any payer-specific separation or bundling.
G2082 and G2083 are established Medicare HCPCS pathways that combine an outpatient encounter, esketamine dose range, supervision, and post-administration observation. They are not universal payer instructions. Commercial plans, Medicaid programs, Medicare contractors, buy-and-bill arrangements, specialty-pharmacy pathways, and patient-supplied drug policies can differ.
Key takeaways
The short version
- Confirm whether the payer expects a bundled encounter or separate drug and professional reporting.
- Do not infer current Medicare coverage from a code's existence or an old contractor article.
- Reconcile ordered, authorized, acquired, received, administered, wasted, and billed drug quantities.
- Treat REMS compliance and claim support as linked but separate controls.
- Version payer rules, FDA label, HCPCS files, coverage documents, and test claims.
Take the template with you
Free to copy · no email required
Reconcile authorization, acquisition, dose, observation, billing architecture, remittance, and inventory.
patient_case_id,payer,product,authorization,dose_authorized,frequency_authorized,site,provider,acquisition_path,shipment_id,product_quantity_received,treatment_date,dose_ordered,dose_administered,observation_complete,disposition,code_or_architecture,units_billed,claim_id,acceptance,remittance,denial_reason,inventory_variance,owner,status,notes ,,,,,,,,,,,,,,,,,,,,,,,,,
1. Choose the payer's billing architecture
| Architecture | What it may represent | Verify before use |
|---|---|---|
| G2082 pathway | Qualifying outpatient encounter, up to 56 mg, supervision, and observation | Payer acceptance, coverage, setting, provider, dose, authorization, and documentation |
| G2083 pathway | Qualifying outpatient encounter above 56 mg, supervision, and observation | Same checks plus the administered dose and current code source |
| Separate drug and service lines | Drug supply plus administration, E/M, or observation under payer rules | Allowed code combination, acquisition source, NDC or units, edits, and included work |
| Specialty-pharmacy or patient-specific drug | Drug may be paid outside the medical claim | Shipment, chain of custody, patient match, no duplicate drug billing, and service-only rule |
| Institutional pathway | Hospital or facility claim structure | Bill type, revenue fields, OPPS status, provider-based rules, and professional split |
| Noncovered or self-pay pathway | Service outside covered benefit under a valid process | Coverage determination, notices, estimate, consent, contract, and patient communication |
2. Read 2026 sources in the correct order
- Current FDA label and REMS materials for approved use, administration, observation, warnings, and certified setting requirements
- July 2026 HCPCS file for current code status and descriptors
- Payer medical and pharmacy policies, provider manual, fee schedule, contract, and acquisition instructions
- For Medicare, the current jurisdiction's active Coverage Database documents and contractor guidance for the service date
- Current NCCI or facility edits, claim companion guide, clearinghouse validation, and remittance
3. Reconcile the drug and visit end to end
- 01
Verify clinical and program readiness
Confirm qualified prescriber, FDA-label context, certified setting, REMS workflow, screening, administration plan, observation, and emergency readiness.
- 02
Verify payer scope
Confirm member, product, benefit, medical versus pharmacy pathway, network, authorization, dose, frequency, diagnosis, site, and provider.
- 03
Resolve acquisition
Identify buy and bill, specialty pharmacy, white bagging, patient-supplied, replacement, or another permitted source and record ownership.
- 04
Capture the treatment session
Record ordered dose, product received, lot or inventory data where required, administered dose, observation, monitoring, disposition, and any waste under policy.
- 05
Construct and review the claim
Use the payer's bundled or separated architecture; validate codes, units, identifiers, modifiers, diagnosis, authorization, and included services.
- 06
Reconcile payment and inventory
Link claim, remittance, denial, replacement, refund, waste, and inventory so neither drug nor service is billed twice or lost.
4. Put hard stops at the dangerous handoffs
| Handoff | Hard stop | Risk prevented |
|---|---|---|
| Authorization to order | Dose, frequency, provider, setting, dates, and approval match | Administered care outside approved scope |
| Shipment to patient | Patient, product, quantity, source, site, and arrival verified | Wrong-patient drug or duplicate acquisition |
| Administration to claim | Ordered, received, administered, observed, and billed quantities reconcile | Unit error or unsupported billing |
| Bundle to separate lines | Qualified review confirms allowed architecture and no duplicate included work | Unbundling and edit denials |
| Coverage article to configuration | Status, jurisdiction, version, and effective dates verified | Reliance on retired local guidance |
| Remittance to inventory | Payment, denial, replacement, return, and waste resolved | Revenue leakage and inventory mismatch |
5. Monitor a SPRAVATO revenue-and-safety scoreboard
- Authorization turnaround, expiration, approved dose and frequency, and treatment delay
- Drug acquisition source, shipment exceptions, inventory variance, waste, and replacement
- Sessions completed, observation documented, disposition complete, and missing-record holds
- First-pass acceptance, denial reason, days to bill, days to payment, recovery, and patient estimate variance
- Bundled versus separate architecture by payer and product
- Source age, coverage-document status, configuration review, and test-claim results
Common questions
Answers before you build.
What are G2082 and G2083 used for?+
They are Medicare HCPCS pathways for qualifying outpatient esketamine encounters that incorporate dose range, supervision, and post-administration observation. Current payer acceptance and coverage must still be verified.
Can SPRAVATO be billed with a separate drug code?+
It depends on the payer's billing and acquisition architecture. Some pathways bundle drug and observation; others may separate drug and professional or facility reporting. Verify included work and edits before billing.
Does REMS certification guarantee insurance coverage?+
No. REMS addresses medication safety controls. Coverage, authorization, network, acquisition, coding, documentation, and payment are separate payer decisions.
Why should teams check the Medicare Coverage Database for every jurisdiction?+
Medicare contractor articles can have different status, versions, effective dates, and jurisdictions. An older article or a code's existence does not establish current coverage.
Practical closeout
Use this operator checklist.
- Confirm whether the payer expects a bundled encounter or separate drug and professional reporting.
- Do not infer current Medicare coverage from a code's existence or an old contractor article.
- Reconcile ordered, authorized, acquired, received, administered, wasted, and billed drug quantities.
- Treat REMS compliance and claim support as linked but separate controls.
- Version payer rules, FDA label, HCPCS files, coverage documents, and test claims.
Continue through the cluster
Verified customer case studies are added only with customer permission and supporting evidence; none is implied by these operational examples.
Sources & methodology
Trace the operational claims.
Marsa Health Editorial reviewed the primary and research sources below on July 28, 2026. We translate them into workflow controls, distinguish proposals from final rules, and flag where plan, program, state, contract, or clinical requirements vary.
- 01SPRAVATO Current FDA Label Record U.S. Food and Drug AdministrationCurrent FDA label record for SPRAVATO, including approved use, warnings, administration, observation, and REMS requirements.Accessed or rechecked July 28, 2026
- 02Risk Evaluation and Mitigation Strategies U.S. Food and Drug AdministrationFDA overview of REMS requirements and current program materials.Accessed or rechecked July 28, 2026
- 03HCPCS Quarterly Update Centers for Medicare & Medicaid ServicesOfficial quarterly HCPCS files, including the July 2026 alpha-numeric update current when this guide was reviewed.Accessed or rechecked July 28, 2026
- 04Billing and Coding: Esketamine Centers for Medicare & Medicaid ServicesMedicare contractor billing article illustrating esketamine coding and documentation; teams must verify current status, version, jurisdiction, and service date before relying on it.Accessed or rechecked July 28, 2026
- 05Medicare Coverage Database Centers for Medicare & Medicaid ServicesOfficial search for current national and local Medicare coverage documents by service, jurisdiction, status, and effective version.Accessed or rechecked July 28, 2026
- 06Autism services Medicaid.govFederal Medicaid overview and guidance collection on autism services; state coverage and operational requirements vary.Accessed or rechecked July 28, 2026
- 07CMS Interoperability and Prior Authorization Final Rule CMS-0057-F Centers for Medicare & Medicaid ServicesCurrent implementation dates, decision timeframes, denial-reason requirements, metrics, and API provisions for impacted payers.Accessed or rechecked July 28, 2026
- 08Minimum Necessary Requirement U.S. Department of Health and Human ServicesHIPAA guidance on limiting uses, disclosures, and requests for protected health information when the standard applies.Accessed or rechecked July 28, 2026
Organizational author. Editorial review covers source accuracy, search intent, workflow boundaries, and human-oversight requirements. This material is educational and does not provide clinical, legal, coding, or coverage advice.
No named clinical or legal expert reviewer is attributed to this version. Marsa Health does not invent reviewer credentials.
Read our editorial methodRevision history
What changed and when
July 28, 2026
Initial publication, source review, and operational editing.